All News

Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)

d Jack Cush, MD

This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
computer.health.jpg (keep)

Patient Perspectives on Telemedicine Use During the Pandemic

d Jack Cush, MD

Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients.

Read Article
While COVID rates are near historic lows & far less dangerous, hospitalizations are up 10.3%, ER visits up 7%, pos. tests rose to 6.3% from 5.8% in the last week https://t.co/TFAt4p24au

Links:

Dr. John Cush RheumNow ( View Tweet)

vaccination.jpg

Hold the Methotrexate for One Week

d Jack Cush, MD

In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.

Read Article
RA Biologics Lower COVID-19 Deaths, but Not Recovery Time Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care? https://t.co/o56m9WumiC. https://t.co/GHe1RprDnk

Links:

Dr. John Cush RheumNow ( View Tweet)
Covid lung pneumonia corona (keep)

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time

d Jack Cush, MD

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

Read Article
An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately given METFORMIN or Placebo. Cumulative incidence of long COVID at day 300 was 6.3% w/ metformin vs 10.4% w/ placebo (HR 0.59; HR 037 if given w/in 3d) https://t.co/aCTX7xFewW https://t.co/xbBeED9K7U

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

What is Colchicine Worth? (6.23.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

Read Article
Factors associated with higher prevalence of post COVID-19 condition include female sex, age, asthma, diabetes, hypertension, number of symptoms in the acute phase and possible mechanisms causing the syndrome, Mayssam Nehme, COVID-19, #EULAR2023 https://t.co/IzHEQqfPb1
Dr. Antoni Chan synovialjoints ( View Tweet)
Reflections on COVID-19 and autoimmunity: post-vaccination autoimmunity is not specific to COVID-19, autoimmunity is not autoimmune disease, the large numbers may result in the perception of increased occurrence of autoimmunity, Schulze-Koops H, COVID-19, #EULAR2023 @RheumNow https://t.co/Rm9OEWrBzo
Dr. Antoni Chan synovialjoints ( View Tweet)
Factors related to having a flare of arthritis during COVID-19 include female gender, higher disease activity, no DMARD at time of vaccination. Stopping DMARDs need to be weighed up against risk of flares, Pedro Machado, COVID-19 #EULAR2023 @RheumNow https://t.co/3sd32tF2kW
Dr. Antoni Chan synovialjoints ( View Tweet)
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
Lit review of 2236 articles found only 28 w/ Post-COVID autoimmune Dx (64% F; age 51 yrs) - that included 11 (39) IIM (w/ 4 DM); 7 (25%) SLE; 4 (14%) anti-synthetase syndrome; 4 (14%) SSc; 1 lupus/MCTD overlap. Mean onset 23.7 d post COVID https://t.co/jtRaqIBGH1 https://t.co/WilcRFNAL9

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

One in Ten is Bad! (5.12.2023)

d Jack Cush, MD

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article
TB.EMimage.CDC_.jpg

2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections

d Jack Cush, MD

Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised.

Read Article
in 2022 COVID slid from the #3 to the #4 cause of death in USA, accounting for nearly a quarter million deaths, a 47 percent decrease from the 462,193 Covid-related deaths in 2021. Most COVID deaths occured in the first few mos of 2022 https://t.co/qervCp0P87 https://t.co/WN7DvsFhNC

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID had a significant effect on mental health of inflammatory rheumatic Dz (IRDs) pts. UK NHS survey of 639 IRD (70% RA, 16% PsA) saw 40% w/ mod/severe pandemic impact on physical & mental health; 29% w/ depression, 22% anxiety; affecting Women>males https://t.co/kcAwa2Lks2 https://t.co/R6tk2aOrGQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Industry Payments to Rheums Dropped During COVID Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that payments from industry dried up as well. https://t.co/jsxw23tTyY https://t.co/5PiaRpiSa4

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×